Article
Multidisciplinary Sciences
Rongshou Wu, Weiwei Liu, Qingping Yang, Jingling Zhang, Ping Hou, Jianghui Xiong, Linquan Wu, Enliang Li
Summary: This study found that TUG1 could regulate the expression of PD-L1 through JAK2/STAT3 pathway to mediate immunosuppression. TUG1 and PD-L1 were highly expressed in HCC tissues and cancer cells, and their high expression was associated with poor prognosis of HCC patients. Silencing TUG1 expression could reduce PD-L1 expression and enhance the cancer cell-killing capability of T cells.
SCIENTIFIC REPORTS
(2023)
Review
Immunology
Qian Li, Jingjing Han, Yonglin Yang, Yu Chen
Summary: Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide. In recent years, immunotherapy using immune checkpoint inhibitors, particularly targeting the PD-1/PD-L1 axis, has brought fundamental changes to the treatment of advanced HCC. However, challenges remain and combination therapy may be a better option to improve the low remission rate.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Jie Li, Lijuan Zhang, Yun Tao, Zongqiong Sun, Yuxi Ge, Shudong Hu
Summary: This study aimed to investigate the effects of combination TACE and anti-PD-L1 liposome drug therapy on HCC in mice models. The liposome drug was successfully constructed and the HCC mice model was established. Results showed that the combined treatment significantly reduced the volume of hepatic carcinoma tissues and increased the apoptotic rate of hepatic carcinoma cells. Additionally, the treatment had regulatory effects on protein and gene expressions.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2023)
Article
Medicine, Research & Experimental
Meng Gao, Dongjian Zhang, Cuihua Jiang, Qiaomei Jin, Jian Zhang
Summary: Paeoniflorin inhibits PD-L1 expression on hepatocellular carcinoma (HCC) cells and exhibits anti-tumor effects by promoting T cell-mediated immune responses. Paeoniflorin also suppresses PD-L1 expression through the SOCS3/STAT3 signaling pathway. These findings provide novel insights into the anticancer effects of paeoniflorin.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Health Care Sciences & Services
Stefano Marletta, Nicola Fusco, Enrico Munari, Claudio Luchini, Alessia Cimadamore, Matteo Brunelli, Giulia Querzoli, Maurizio Martini, Elena Vigliar, Romano Colombari, Ilaria Girolami, Fabio Pagni, Albino Eccher
Summary: This paper provides an update on the assessment of PD-L1 expression in various types of tumors. While robust data and specific protocols are available for some tumors, further studies and clinical trials are needed to harmonize the topic in other less explored fields.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Li-Gong Lu, Zhi-Ling Zhou, Xu-Yan Wang, Bo-Yuan Liu, Jin-Ying Lu, Shuai Liu, Guang-Bo Zhang, Mei-Xiao Zhan, Yun Chen
Summary: In hepatocellular carcinoma (HCC), PD-L1(+) host macrophages are a major cellular source of PD-L1 in tumors, displaying a glycolytic phenotype and producing antitumor IL-12p70. The regulation of these macrophages involves fibronectin 1-induced PKM2, controlling both antitumor properties and inflammation-mediated PD-L1 expression. Modulating the context of glycolytic macrophages in HCC tumors may restore their antitumor properties and offer a precise strategy for anticancer therapy.
Article
Chemistry, Medicinal
Chengliang Sun, Mingxiao Yin, Yao Cheng, Zean Kuang, Xiaojia Liu, Gefei Wang, Xiao Wang, Kai Yuan, Wenjian Min, Jingwen Dong, Yi Hou, Lingrong Hu, Guoyu Zhang, Wenli Pei, Liping Wang, Yanze Sun, Xinmiao Yu, Yibei Xiao, Hongbin Deng, Peng Yang
Summary: S4-1 is an innovative small-molecule inhibitor of PD-L1 that effectively alters the PD-L1/PD-1 interaction, enhances cytotoxicity of immune cells towards tumor cells, and shows significant tumor growth inhibition in vivo. It also activates T-cells and reverses the inhibitory tumor microenvironment.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Oncology
Yvette Robbins, Jay Friedman, Paul E. Clavijo, Cem Sievers, Ke Bai, Renee N. Donahue, Jeffrey Schlom, Andrew Sinkoe, Christian S. Hinrichs, Clint Allen, Houssein Abdul Sater, James L. Gulley, Scott Norberg
Summary: In this study, dual PD-L1/TGF-b inhibition did not effectively inhibit papilloma growth in RRP patients and even increased the need for clinical interventions in some subjects post-treatment. TGF-b neutralization decreased proliferation within papillomas, indicating that intact TGF-b signaling restrains proliferation. Dual PD-L1/TGF-b inhibition did not enhance anti-HPV immunity within papillomas beyond what was observed with PD-L1 blockade.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Mengxiang Zhao, Yijia He, Nisha Zhu, Yuxian Song, Qingang Hu, Zhiyong Wang, Yanhong Ni, Liang Ding
Summary: This study found that IL-33/ST2 signaling pathway can enhance PD-L1-mediated immune escape, and ST2 high-expression OSCC patients may benefit from anti-PD-1/L1 therapy.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Jake G. Maule, Lani K. Clinton, Ryon P. Graf, Jinpeng Xiao, Geoffrey R. Oxnard, Jeffrey S. Ross, Richard S. P. Huang
Summary: This study analyzed 418 tumor specimens using 22C3, 28-8, and SP142 PD-L1 IHC assays and found that 22C3 is the most sensitive assay. This finding can assist clinical teams in determining which PD-L1 IHC assay to use for each patient.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Multidisciplinary Sciences
Changsheng Huang, Shengxiang Ren, Yaqi Chen, Anyi Liu, Qi Wu, Tao Jiang, Panjing Lv, Da Song, Fuqing Hu, Jingqing Lan, Li Sun, Xue Zheng, Xuelai Luo, Qian Chu, Keyi Jia, Yan Li, Jun Wang, Caicun Zou, Junbo Hu, Guihua Wang
Summary: This research discovered that PD-L1 K162 was methylated by SETD7 and demethylated by LSD2. Additionally, PD-L1 K162 methylation controlled the PD1/PD-L1 interaction and significantly enhanced the suppression of T cell activity in controlling cancer immune surveillance. The study demonstrated that PD-L1 hypermethylation was the key mechanism for anti-PD-L1 therapy resistance, identified PD-L1 K162 methylation as a negative predictive marker for anti-PD-1 treatment in patients with non-small cell lung cancer, and showed that the PD-L1 K162 methylation:PD-L1 ratio was a more accurate biomarker for predicting anti-PD-(L)1 therapy sensitivity.
Article
Pharmacology & Pharmacy
Yun Liu, Qian Xie, Yao Ma, Chen Lin, Jinlin Li, Bing Hu, Chaoqi Liu, Yun Zhao
Summary: This study investigates the combined anti-tumor activity of targeted nanobubbles (NBs) loaded with PD-L1 antibody and miR-424 gene. The results demonstrate the synergistic anti-tumor immunotherapy effect of ultrasound-mediated targeted NBs, which can enhance the antitumor immune effect mediated by T cells.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2022)
Review
Biotechnology & Applied Microbiology
Gang Yuan, Zhiyin Liu, Weiming Wang, Mengnan Liu, Yanneng Xu, Wei Hu, Yao Fan, Xun Zhang, Yong Liu, Guangyan Si
Summary: Hepatocellular carcinoma (HCC) is a major global health concern with high incidence and mortality rates. Transarterial chemoembolization (TACE) is commonly used for the treatment of unresectable HCC, but its therapeutic effect is often limited. Recent research has focused on using nanomaterials as a drug delivery platform to improve the distribution and bioavailability of drugs in tumor tissues. Functionalized nanomaterials have been developed for targeted embolization, controlled drug release, and real-time imaging, aiming to enhance the therapeutic effect of TACE against HCC.
JOURNAL OF NANOBIOTECHNOLOGY
(2023)
Article
Oncology
LeAnne Young, Shanda Finnigan, Howard Streicher, Helen X. Chen, James Murray, H. Nida Sen, Elad Sharon
Summary: Ocular adverse events are rare complications of PD-1/PD-L1 inhibitor therapy, but can be severe enough to cause treatment discontinuation or delay. Proper evaluation by eye specialists is necessary in managing these adverse events.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Medicine, General & Internal
Karmele Saez de Gordoa, Ingrid Lopez, Marta Marginet, Berta Coloma, Gerard Frigola, Naiara Vega, Daniel Martinez, Cristina Teixido
Summary: The study examined the histological features of PD-L1 cases in NSCLC from 2017 to 2020 and found significant differences in PD-L1 expression among different tumor histological types and sample types. Some cases showed heterogeneity, highlighting the potential impact on eligibility for immunotherapy treatment.
Article
Pathology
Kirill A. Lyapichev, Sergio Pina-Oviedo, L. Jeffrey Medeiros, Mark G. Evans, Hui Liu, Alonso R. Miranda, Kelly K. Hunt, Mark W. Clemens, John M. Stewart, Mitual B. Amin, Andres E. Quesada, Siaw Ming Chai, Arianna Di Napoli, Arthy Yoga, Sanat K. Dave, Ignacio I. Wistuba, Yun Wu, Carlos E. Bueso-Ramos, Ellen J. Schlette, Maria C. Ferrufino-Schmidt, Sanam Loghavi, Joseph D. Khoury, Ken H. Young, Roberto N. Miranda
Editorial Material
Hematology
Hui Liu, Shimin Hu
Letter
Hematology
Zimu Gong, Ting Zhou, Hui Liu, Guilin Tang, C. Cameron Yin, Wei Wang, L. Jeffrey Medeiros, Shimin Hu
BRITISH JOURNAL OF HAEMATOLOGY
(2020)
Article
Oncology
Xiao-Peng Tian, Ning Su, Liang Wang, Wei-Juan Huang, Yan-Hui Liu, Xi Zhang, Hui-Qiang Huang, Tong-Yu Lin, Shu-Yun Ma, Hui-Lan Rao, Mei Li, Fang Liu, Fen Zhang, Li-Ye Zhong, Li Liang, Xiao-Liang Lan, Juan Li, Bing Liao, Zhi-Hua Li, Qiong-Lan Tang, Qiong Liang, Chun-Kui Shao, Qiong-Li Zhai, Run-Fen Cheng, Qi Sun, Kun Ru, Xia Gu, Xi-Na Lin, Kun Yi, Yue-Rong Shuang, Xiao-Dong Chen, Wei Dong, Cai Sun, Wei Sang, Hui Liu, Zhi-Gang Zhu, Jun Rao, Qiao-Nan Guo, Ying Zhou, Xiang-Ling Meng, Yong Zhu, Chang-Lu Hu, Yi-Rong Jiang, Ying Zhang, Hong-Yi Gao, Wen-Jun He, Zhong-Jun Xia, Xue-Yi Pan, Lan Hai, Guo-Wei Li, Li-Yan Song, Tie-Bang Kang, Dan Xie, Qing-Qing Cai
CLINICAL CANCER RESEARCH
(2020)
Article
Cell Biology
Hui Liu, Cheng Chen, Dongshen Ma, Yubing Li, Qianqian Yin, Qing Li, Chenxi Xiang
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2020)
Article
Oncology
Hui Liu, Chenxi Xiang, Mei Wu, Shimin Hu
FRONTIERS IN ONCOLOGY
(2020)
Article
Oncology
Wei Sang, Ming Shi, Jingjing Yang, Jiang Cao, Linyan Xu, Dongmei Yan, Meixue Yao, Hui Liu, Weidong Li, Bing Zhang, Kemeng Sun, Xuguang Song, Cai Sun, Jun Jiao, Yuanyuan Qin, Tingting Sang, Yuanyuan Ma, Mei Wu, Xiang Gao, Hai Cheng, Zhiling Yan, Depeng Li, Haiying Sun, Feng Zhu, Ying Wang, Lingyu Zeng, Zhenyu Li, Junnian Zheng, Kailin Xu
Article
Pathology
Xiao Huang, Qingqing Ding, Hua Guo, Yun Gong, Jun Zhao, Min Zhao, Dawen Sui, Yun Wu, Hui Chen, Hui Liu, Jinxia Zhang, Erika Resetkova, Stacy L. Moulder, Wei-Lien Wang, Lei Huo
Summary: The study compared the concordance of three PD-L1 assays in TNBC, finding that 28-8 and 22C3 had higher positive rates and good agreement in scoring methods, while SP142 showed lower concordance with the other assays. When using SP142 as a reference, optimal agreement was achieved by selecting specific cutoff values for IC, TC, and TCIC/CPS.
Article
Oncology
Zhihong Hu, Zenggang Pan, Weina Chen, Yang Shi, Wei Wang, Ji Yuan, Endi Wang, Shanxiang Zhang, Habibe Kurt, Brenda Mai, Xiaohui Zhang, Hui Liu, Adan A. Rios, Hilary Y. Ma, Nghia D. Nguyen, L. Jeffrey Medeiros, Shimin Hu
Summary: Primary effusion lymphoma (PEL) is a rare large B-cell lymphoma associated with HHV8 infection, presenting mainly as effusion with occasional extracavitary mass. Clinicopathological features of PEL are associated with disease type and HIV status, and the prognosis is poor regardless of presentation or HIV status.
Editorial Material
Hematology
Hui Liu, Shimin Hu
Article
Cell Biology
Hui Liu, Zijun Y. Xu-Monette, Guilin Tang, Wei Wang, Young Kim, Ji Yuan, Yu Li, Weina Chen, Yanping Li, George Y. Fedoriw, Feng Zhu, Xiaosheng Fang, Catherine Luedke, L. Jeffrey Medeiros, Ken H. Young, Shimin Hu
Summary: This study identified 16 cases of EBV+ DHL/THL, with half presenting high-grade/Burkitt-like morphology and the other half diffuse large B cell lymphoma morphology. Using Hans' algorithm, 13 cases were classified as germinal centre B cell and 3 as non-GCB. Most cases showed EBV latency Type I, with a median of 80% positive cells for EBV-encoded small RNAs.
Article
Oncology
Hua Guo, Qingqing Ding, Yun Gong, Michael Z. Gilcrease, Min Zhao, Jun Zhao, Dawen Sui, Yun Wu, Hui Chen, Hui Liu, Jinxia Zhang, Erika Resetkova, Stacy L. Moulder, Wei-Lien Wang, Lei Huo
BREAST CANCER RESEARCH
(2020)
Article
Medicine, Research & Experimental
Jun Ye, Mei Lin, Chuanmeng Zhang, Xiaowei Zhu, Sumeng Li, Hui Liu, Jianfeng Yin, Hong Yu, Kuichun Zhu
BIOMEDICAL REPORTS
(2020)
Meeting Abstract
Medicine, Research & Experimental
Hui Liu, Chenxi Xiang, Dongshen Ma
LABORATORY INVESTIGATION
(2020)
Meeting Abstract
Pathology
Hui Liu, Chenxi Xiang, Dongshen Ma
